Hepatology research group Publications
Publications 2024
-
Liver stiffness and associated risk factors among people with a history of injecting drugs: a prospective cohort study
Subst Abuse Treat Prev Policy, 19 (1), 21
DOI 10.1186/s13011-024-00603-z, PubMed 38532435 -
[Not Available]
Tidsskr Nor Laegeforen, 144 (9)
DOI 10.4045/tidsskr.24.0365, PubMed 39166991 -
Virologic Response and Reinfection Following HCV Treatment among Hospitalized People Who Inject Drugs: Follow-Up Data from the OPPORTUNI-C Trial
Viruses, 16 (6)
DOI 10.3390/v16060858, PubMed 38932151 -
Treatment completion and SVR in the context of HCV elimination: Time to let go of the reins?
Clin Infect Dis (in press)
DOI 10.1093/cid/ciae298, PubMed 38824443 -
Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial
Clin Infect Dis, 78 (3), 582-590
DOI 10.1093/cid/ciad711, PubMed 37992203
Publications 2023
-
[The FIB-4 test as a decision-making tool]
Tidsskr Nor Laegeforen, 143 (5)
DOI 10.4045/tidsskr.23.0176, PubMed 36987901 -
Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study
Int J Drug Policy, 116, 104044
DOI 10.1016/j.drugpo.2023.104044, PubMed 37149914 -
Towards elimination of hepatitis C in Oslo: Cross-sectional prevalence studies among people who inject drugs
Int J Drug Policy, 123, 104279
DOI 10.1016/j.drugpo.2023.104279, PubMed 38061225 -
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
Lancet Gastroenterol Hepatol, 8 (10), 879-907
DOI 10.1016/S2468-1253(23)00197-8, PubMed 37517414
Publications 2022
-
[Transjugular intrahepatic portosystemic shunt for portal hypertension]
Tidsskr Nor Laegeforen, 142 (14)
DOI 10.4045/tidsskr.21.0911, PubMed 36226423 -
Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugs
Liver Int, 42 (6), 1268-1277
DOI 10.1111/liv.15266, PubMed 35362660 -
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
Lancet Gastroenterol Hepatol, 7 (5), 396-415
DOI 10.1016/S2468-1253(21)00472-6, PubMed 35180382 -
[We need a new strategy for liver disease]
Tidsskr Nor Laegeforen, 142 (3)
DOI 10.4045/tidsskr.21.0892, PubMed 35170917
Publications 2021
-
Hepatitis C reinfection in former and active injecting drug users in Belgium
Harm Reduct J, 18 (1), 102
DOI 10.1186/s12954-021-00552-x, PubMed 34641896 -
Hepatitis C in Iceland: a milestone for global elimination
Lancet Gastroenterol Hepatol, 6 (8), 599-600
DOI 10.1016/S2468-1253(21)00182-5, PubMed 34171268 -
Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV)
PLoS Med, 18 (6), e1003653
DOI 10.1371/journal.pmed.1003653, PubMed 34061883 -
Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial
BMJ Open, 11 (6), e048541
DOI 10.1136/bmjopen-2020-048541, PubMed 34168032 -
Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway
Int J Drug Policy, 96, 103165
DOI 10.1016/j.drugpo.2021.103165, PubMed 33642182 -
In Well-Treated Celiac Patients Low-Level Mucosal Inflammation Predicts Response to 14-day Gluten Challenge
Adv Sci (Weinh), 8 (4), 2003526
DOI 10.1002/advs.202003526, PubMed 33643806 -
Successful Control of Hepatitis B Virus Reactivation following Restart of Ibrutinib in Chronic Lymphocytic Leukaemia
Case Rep Hematol, 2021, 1862446
DOI 10.1155/2021/1862446, PubMed 34721911 -
[Diagnosis and treatment of autoimmune hepatitis]
Tidsskr Nor Laegeforen, 141 (10)
DOI 10.4045/tidsskr.20.1045, PubMed 34182737
Publications 2020
-
Effect of gender on mortality and causes of death in cirrhotic patients with gastroesophageal varices. A retrospective study in Norway
PLoS One, 15 (3), e0230263
DOI 10.1371/journal.pone.0230263, PubMed 32163489 -
Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs
Trials, 21 (1), 524
DOI 10.1186/s13063-020-04434-8, PubMed 32539853 -
A man in his 50s with chronic diarrhea and weight loss
Tidsskr. Nor. Laegeforen., 140 (11), 1148-1151 -
[A man in his fifties with chronic diarrhoea and weight loss]
Tidsskr Nor Laegeforen, 140 (11)
DOI 10.4045/tidsskr.19.0812, PubMed 32815334
Publications 2019
-
Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV)
BMC Infect Dis, 19 (1), 943
DOI 10.1186/s12879-019-4598-7, PubMed 31703669 -
Mosaic deletion patterns of the human antibody heavy chain gene locus shown by Bayesian haplotyping
Nat Commun, 10 (1), 628
DOI 10.1038/s41467-019-08489-3, PubMed 30733445 -
Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease
Sci Adv, 5 (8), eaaw7756
DOI 10.1126/sciadv.aaw7756, PubMed 31457091 -
Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis
J Hepatol, 72 (4), 643-657
DOI 10.1016/j.jhep.2019.11.012, PubMed 31785345 -
The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination
Clin Infect Dis, 69 (12), 2218-2227
DOI 10.1093/cid/ciz714, PubMed 31352481 -
The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients
Scand J Gastroenterol, 54 (9), 1172-1175
DOI 10.1080/00365521.2019.1643403, PubMed 31479286 -
Cytokine release after gluten ingestion differentiates coeliac disease from self-reported gluten sensitivity
United European Gastroenterol J, 8 (1), 108-118
DOI 10.1177/2050640619874173, PubMed 32213060 -
How can we achieve WHO's elimination target for hepatitis C incidence?
Lancet Gastroenterol Hepatol, 4 (6), 415-417
DOI 10.1016/S2468-1253(19)30120-7, PubMed 30981687
Publications 2018
-
Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework
Liver Int, 39 (1), 20-30
DOI 10.1111/liv.13949, PubMed 30157316 -
Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe
J Hepatol, 68 (3), 402-411
DOI 10.1016/j.jhep.2017.10.010, PubMed 29080808 -
Hepatitis C in drug addicts
Tidsskr. Nor. Laegeforen., 138 (13), 1243 -
[Elimination of hepatitis C is possible]
Tidsskr Nor Laegeforen, 138 (7)
DOI 10.4045/tidsskr.18.0099, PubMed 29663789 -
Elimination of Hepatitis C is possible
Tidsskr. Nor. Laegeforen., 138 (7), 630-633 -
Disease-driving CD4+ T cell clonotypes persist for decades in celiac disease
J Clin Invest, 128 (6), 2642-2650
DOI 10.1172/JCI98819, PubMed 29757191
Publications 2017
-
Increased hope following successful treatment for hepatitis C infection
J Adv Nurs, 74 (3), 724-733
DOI 10.1111/jan.13487, PubMed 29082540 -
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study
BMC Infect Dis, 17 (1), 420
DOI 10.1186/s12879-017-2517-3, PubMed 28610605 -
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs
Int J Drug Policy, 47, 51-60
DOI 10.1016/j.drugpo.2017.05.019, PubMed 28683982 -
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study
Int J Drug Policy, 47, 177-186
DOI 10.1016/j.drugpo.2017.05.020, PubMed 28624134 -
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study
Int J Drug Policy, 47, 230-238
DOI 10.1016/j.drugpo.2017.05.040, PubMed 28633998 -
HLA-DQ-Gluten Tetramer Blood Test Accurately Identifies Patients With and Without Celiac Disease in Absence of Gluten Consumption
Gastroenterology, 154 (4), 886-896.e6
DOI 10.1053/j.gastro.2017.11.006, PubMed 29146521 -
HLA-DQ:gluten tetramer test in blood gives better detection of coeliac patients than biopsy after 14-day gluten challenge
Gut, 67 (9), 1606-1613
DOI 10.1136/gutjnl-2017-314461, PubMed 28779027 -
Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity
Gastroenterology, 154 (3), 529-539.e2
DOI 10.1053/j.gastro.2017.10.040, PubMed 29102613
Publications 2016
-
Hepatitis C reinfection after sustained virological response
J Hepatol, 64 (5), 1020-1026
DOI 10.1016/j.jhep.2016.01.001, PubMed 26780289 -
Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study
PLoS One, 11 (11), e0166451
DOI 10.1371/journal.pone.0166451, PubMed 27846264 -
HCV epidemiology in high-risk groups and the risk of reinfection
J Hepatol, 65 (1 Suppl), S33-S45
DOI 10.1016/j.jhep.2016.07.012, PubMed 27641987
Publications 2015
-
Randomised controlled trial of temoporfin photodynamic therapy plus chemotherapy in nonresectable biliary carcinoma--PCS Nordic study
Photodiagnosis Photodyn Ther, 13, 330-333
DOI 10.1016/j.pdpdt.2015.09.004, PubMed 26415549 -
Increased Serum Levels of LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease: Possible Role in Hepatic Inflammation
Clin Transl Gastroenterol, 6 (7), e95
DOI 10.1038/ctg.2015.23, PubMed 26133108
Publications 2013
-
Quantitative measurement of ultrasound attenuation and Hepato-Renal Index in Non-Alcoholic Fatty Liver Disease
Med Ultrason, 15 (1), 16-22
DOI 10.11152/mu.2013.2066.151.hlv1qmu2, PubMed 23486619
Publications 2012
-
Combining transient elastography with FIB4 enhances sensitivity in detecting advanced fibrosis of the liver
Scand J Gastroenterol, 48 (1), 93-100
DOI 10.3109/00365521.2012.746389, PubMed 23205894 -
A young woman with upper gastrointestinal bleeding
Tidsskr Nor Laegeforen, 132 (18), 2070-2
DOI 10.4045/tidsskr.11.1197, PubMed 23038199
Publications 2011
-
Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs
Scand J Gastroenterol, 46 (6), 760-6
DOI 10.3109/00365521.2011.565068, PubMed 21438780 -
A rapid chemokine response of macrophage inflammatory protein (MIP)-1α, MIP-1β and the regulated on activation, normal T expressed and secreted chemokine is associated with a sustained virological response in the treatment of chronic hepatitis C
Clin Microbiol Infect, 17 (2), 204-9
DOI 10.1111/j.1469-0691.2010.03206.x, PubMed 20219081 -
Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies
Eur J Endocrinol, 166 (3), 503-10
DOI 10.1530/EJE-11-0864, PubMed 22170794 -
Activin A in nonalcoholic fatty liver disease
Vitam Horm, 85, 323-42
DOI 10.1016/B978-0-12-385961-7.00015-9, PubMed 21353887
Publications 2010
-
Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease
J Clin Endocrinol Metab, 95 (6), 3039-47
DOI 10.1210/jc.2009-2148, PubMed 20392873 -
Liver fibrosis in hepatitis C patients of Pakistani versus Scandinavian origin
Scand J Gastroenterol, 45 (12), 1503-8
DOI 10.3109/00365521.2010.510571, PubMed 20698740
Publications 2009
-
Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial
Scand J Gastroenterol, 44 (7), 853-60
DOI 10.1080/00365520902845268, PubMed 19811343 -
A complex role of activin A in non-alcoholic fatty liver disease
Am J Gastroenterol, 104 (9), 2196-205
DOI 10.1038/ajg.2009.318, PubMed 19532130 -
Hyperinsulinemic hypoglycemia and liver cirrhosis presenting after duodenal switch: a case report
Surg Obes Relat Dis, 6 (4), 441-3
DOI 10.1016/j.soard.2009.11.007, PubMed 20096646
Publications 2008
-
ASAT/ALAT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis
Scand J Gastroenterol, 43 (10), 1241-8
DOI 10.1080/00365520802158614, PubMed 18609128
Publications 2007
-
[When the brain fails in liver failure]
Tidsskr Nor Laegeforen, 127 (11), 1490
PubMed 17551548 -
Incidence rates and causes of cirrhosis in a Norwegian population
Scand J Gastroenterol, 42 (12), 1501-8
DOI 10.1080/00365520701478014, PubMed 17852839 -
Occurrence of hepatoxicicty and elevated liver enzymes in a Crohn's disease patient treated with infliximab
Inflamm Bowel Dis, 13 (12), 1584-6
DOI 10.1002/ibd.20230, PubMed 17663423
Publications 2006
-
Inflammatory interactions between nonalcoholic fatty liver disease and the metabolic syndrome
J. Hepatol., 45 (6), 881-882
DOI 10.1016/j.jhep.2006.09.006 -
Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2
J Hepatol, 44 (6), 1167-74
DOI 10.1016/j.jhep.2006.02.011, PubMed 16618517
Publications 2005
-
Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease
Scand J Gastroenterol, 40 (12), 1469-77
DOI 10.1080/00365520500264953, PubMed 16293559
Publications 2001
-
[Non-alcoholic steatohepatitis]
Tidsskr Nor Laegeforen, 121 (20), 2377-80
PubMed 11603045
Publications 2000
-
[Carbamazepine-induced hepatitis]
Tidsskr Nor Laegeforen, 120 (24), 2875-7
PubMed 11143408
Publications 1999
-
[Severe hypophosphatemia--an overlooked condition?]
Tidsskr Nor Laegeforen, 119 (4), 538-40
PubMed 10081379
Publications 1996
-
[Seroxat combined with Meravean--increased risk of hemorrhage?]
Tidsskr Nor Laegeforen, 116 (29), 3528-9
PubMed 9019863
Publications 1995
-
Interferon-gamma inhibits endocytosis of soluble animated beta-1,3-D-glucan and neutral red in mouse peritoneal macrophages
J Interferon Cytokine Res, 15 (7), 597-603
DOI 10.1089/jir.1995.15.597, PubMed 7553229
Publications 1994
-
The effects of plasma and albumin infusion on organ function and sepsis markers in experimental gram-negative sepsis
Shock, 2 (6), 402-7
DOI 10.1097/00024382-199412000-00003, PubMed 7743369 -
IFN-gamma inhibits internalization of soluble aminated beta-1,3-D-glucan by macrophages and thereby down-regulates the glucan induced release of TNF-alpha and IL-1 beta
Scand J Immunol, 40 (1), 57-63
DOI 10.1111/j.1365-3083.1994.tb03433.x, PubMed 8029644 -
A novel immunomodulator soluble aminated beta-1,3-D-glucan: binding characteristics to mouse peritoneal macrophages
Biochim Biophys Acta, 1221 (1), 61-5
DOI 10.1016/0167-4889(94)90216-x, PubMed 8130277 -
The TNF Receptors p55 and p75 Mediate Chemotaxis of PMN Induced by TNFalpha and a TNFalpha 36-62 Peptide
Mediators Inflamm, 3 (5), 347-52
DOI 10.1155/S0962935194000487, PubMed 18475579
Publications 1993
-
Cytokines and PGE2 modulate the phagocytic function of the beta-glucan receptor in macrophages
Scand J Immunol, 37 (5), 587-92
DOI 10.1111/j.1365-3083.1993.tb02576.x, PubMed 8387227
Publications 1992
-
Killing of Escherichia coli by mononuclear phagocytes and neutrophils stimulated in vitro with beta-1,3-D-polyglucose derivatives
Microbiol Immunol, 36 (11), 1173-88
DOI 10.1111/j.1348-0421.1992.tb02120.x, PubMed 1491620
Publications 1991
-
Phagocytosis of beta-1,3-D-glucan-derivatized microbeads by mouse peritoneal macrophages involves three different receptors
Scand J Immunol, 33 (3), 297-306
DOI 10.1111/j.1365-3083.1991.tb01775.x, PubMed 1849314